AMBITION BTK is a multicenter, randomized controlled trial (RCT) designed to evaluate the clinical outcomes of the Auryon Atherectomy System in combination with standard balloon angioplasty compared ...
As the news cycle goes, headlines are rolling into the January US Federal Open Market Committee meeting that begins today.
Northcott brings over two decades of commercial experience to Nurix, having previously led commercialization efforts for the first marketed BTK inhibitor, ibrutinib. The company, currently valued ...
Learn more. Please also consider subscribing to WIRED It's totally understandable if you haven’t opened Apple Maps since its disastrous launch in 2012, which among other things saw people ...
Credit: Nadezhda Fedrunova via Getty Images. AstraZeneca has received approval from the US Food and Drug Administration (FDA) for its Bruton’s tyrosine kinase (BTK) inhibitor, Calquence (acalabrutinib ...
AstraZeneca’s Calquence became the first BTK inhibitor approved in the US for first-line use in mantle cell lymphoma on Thursday. The drug ...
January 16, 2025—Concept Medical Inc., announced the enrollment of the first patient in the pivotal MAGICAL BTK randomized controlled trial, which is being conducted in the United States under an ...
COOMBS: We have so many effective therapies that it is often difficult to choose. Bruton tyrosine kinase [BTK] inhibitors are the mainstay in CLL, with ibrutinib [Imbruvica] being the first approved, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback